Ecraid has begun its first clinical trial in partnership with specialty vaccine company Valneva, since Ecraid’s formation as a not-for-profit foundation in 2022.
The goal of this Phase 2/3 study is to investigate the safety, tolerability and immunogenicity of a booster vaccination with Valneva’s COVID-19 vaccine, VLA2001, in adults. VLA2001 received marketing authorization in Europe for use as primary immunization in people from 18 to 50 years of age in June 2022.
Strengthening Europe’s clinical research infrastructure
Ecraid is the first network of its kind in Europe to connect its ‘warm-base’ clinical and laboratory research network with governments, public and private organisations to help advance the fight against infectious diseases.
In this collaboration with Valneva, from first contact to protocol approval by the CCMO (Central Committee on Research Involving Human Subjects in the Netherlands), and through to patient enrolment, the trial was set up within just four months and has an estimated completion date of October 2023.
“The COVID-19 pandemic has showcased Ecraid’s operational excellence in executing complex and critical studies. Our partnership with Valneva aims at speeding up the development of a COVID-19 booster vaccine. This is in line with Ecraid’s mission to build a permanent, not-for-profit, pan-European clinical research network that is capable of rapidly initiating and completing high-quality clinical trials, in a faster and more efficient way.” — Marc Bonten, Ecraid CEO.